
Content
Durolane vs Synvisc comes down to three practical differences: where the hyaluronic acid comes from, how many injections a course takes, and which patients need extra caution. Durolane is a single 3 mL injection (60 mg) of non-animal, stabilized hyaluronic acid made by bacterial fermentation. Synvisc is hylan G-F 20, a cross-linked hyaluronan produced from chicken combs, given either as three weekly 2 mL injections (Synvisc) or as one 6 mL injection (Synvisc-One).
All three products carry the same FDA indication: pain in knee osteoarthritis (OA) in patients who have not responded adequately to conservative non-drug therapy and simple analgesics such as acetaminophen. None of them is a steroid, and none rebuilds cartilage. In their pivotal trials both Durolane and Synvisc-One were followed for 26 weeks, which is where the familiar “up to six months” figure comes from.
This guide compares Durolane, Synvisc and Synvisc-One on composition, dosing, trial data, safety, guideline status and billing codes, then looks briefly at other options such as Monovisc, Euflexxa, Orthovisc and Gel-One. It is written for licensed practitioners and clinic buyers, with plain-language notes for patients researching their options.
The table below summarizes the FDA labeling for each product. Durolane data come from the Durolane Instructions for Use filed under PMA P170007; Synvisc and Synvisc-One data come from the current Sanofi prescribing information for Synvisc and Synvisc-One (both revised September 2025).
| Feature | Durolane | Synvisc | Synvisc-One |
|---|---|---|---|
| Manufacturer / US distributor | Q-Med AB / Bioventus | Genzyme (Sanofi) | Genzyme (Sanofi) |
| Hyaluronic acid type | NASHA: non-animal stabilized sodium hyaluronate, bacterial fermentation | Hylan G-F 20: hylan A and hylan B polymers from chicken combs, chemically cross-linked | Hylan G-F 20 (same material as Synvisc) |
| Concentration and volume | 20 mg/mL; 60 mg in 3 mL | 8 mg/mL; 16 mg in 2 mL per injection | 8 mg/mL; 48 mg in 6 mL |
| Injections per course | 1 | 3, one week apart | 1 |
| FDA approval | PMA P170007, August 29, 2017 | PMA P940015, August 8, 1997 | PMA supplement P940015/S012, February 26, 2009 |
| Avian allergy | Not avian-derived; contraindicated only with known hypersensitivity to HA preparations | Labeled precaution for allergy to avian proteins, feathers or egg products | Same precaution as Synvisc |
| Trial follow-up | 26 weeks (CHASE trial vs a 5-injection HA; NASHA vs methylprednisolone trial) | 26 weeks in the longest of its concurrently controlled trials | 26 weeks (placebo-controlled pivotal trial) |
| Common adverse events | Arthralgia, injection-site pain, joint swelling, joint stiffness | Pain, swelling and effusion in the injected knee | Arthralgia, arthritis, arthropathy, injection-site pain, joint effusion |
| Rare but notable | Labeled caution in pre-existing chondrocalcinosis | Acute inflammatory “pseudoseptic” flares described in the literature; rare thrombocytopenia post-marketing | Same hylan G-F 20 post-marketing profile |
| HCPCS code | J7318 (per 1 mg) | J7325 (per 1 mg) | J7325 (per 1 mg) |
The quickest way to read the table: Durolane and Synvisc-One are both one-visit treatments, while classic Synvisc needs three visits. Synvisc-One simply combines the three Synvisc doses into one syringe, so its total hylan dose (48 mg) equals a full three-injection Synvisc course. Durolane delivers a higher total mass of hyaluronic acid (60 mg), but the two materials are built differently, so milligrams are not directly comparable.
Durolane is made with NASHA (non-animal stabilized hyaluronic acid) technology. The FDA-filed labeling describes it this way:
“DUROLANE® is a clear, transparent, viscous gel of highly purified, stabilized, non-animal-derived sodium hyaluronate that is biosynthesized using bacterial fermentation.” FDA, Durolane Instructions for Use (PMA P170007)
Older articles, including an earlier version of this page, called Durolane “synthetic”. That is not accurate: the hyaluronic acid is produced by bacteria and then stabilized into a gel, so it is non-animal rather than synthetic. The stabilization is what allows a single injection to stay in the joint longer than an unmodified sodium hyaluronate solution.
Synvisc and Synvisc-One contain hylan G-F 20, which the label describes as an elastoviscous high molecular weight fluid of hylan A and hylan B polymers produced from chicken combs, with the hyaluronan chemically cross-linked. Earlier claims that Synvisc has a “lower molecular weight” than Durolane are also wrong; hylan G-F 20 is labeled as high molecular weight, and the three-injection schedule reflects how the product was originally developed and approved, not a weaker molecule.
Interest in the source of hyaluronic acid is mostly practical. A patient with a documented allergy to eggs, feathers or poultry is easier to manage with a non-avian product such as Durolane, while for most other patients the choice turns on visit count, reimbursement and clinician experience. Licensed buyers can order Durolane 60 mg/3 mL or review the Synvisc range through a verified OGOmed account.
Orthopedics products
17 products available
Explore our Orthopedics products collection and browse available products.
View category
Searches for “Durolane injection reviews” and “Durolane injection success rate” are common, but patient reviews cannot separate the product’s effect from the strong placebo response seen with any knee injection. Controlled trials are a better guide.
Durolane. In the CHASE trial, published in Arthritis Research & Therapy (2015), 349 patients in China received either one 3 mL Durolane injection or five weekly injections of Artz. Durolane was non-inferior over 18 and 26 weeks for pain, function and stiffness; treatment-related adverse events were 13.1% with Durolane and 9.8% with Artz. This study was the pivotal dataset for US approval. A second trial, published in Osteoarthritis and Cartilage (2014), randomized 442 patients to NASHA or methylprednisolone acetate. Responder rates at 12 weeks were 44.6% and 46.2%, meeting the non-inferiority goal, and the benefit of NASHA was maintained to 26 weeks while that of the steroid declined. The FDA labeling is candid that two earlier saline-controlled Durolane trials did not show superiority over saline.
Synvisc-One. The pivotal trial, published in Annals of the Rheumatic Diseases (2010), randomized 253 patients to one 6 mL injection of hylan G-F 20 or placebo. Synvisc-One produced statistically significant pain relief over 26 weeks, which the authors described as a modest difference versus placebo. The three-injection Synvisc regimen was studied in several smaller concurrently controlled trials summarized in its label.
Head-to-head data. We could not find a large randomized trial comparing Durolane directly with Synvisc or Synvisc-One in PubMed. Any claim that one is clearly “better” is therefore an extrapolation across trials with different comparators. It is also worth knowing that a 2026 single-center trial in JB JS Open Access found no difference in pain between single-injection hylan G-F 20, another cross-linked HA and saline over 24 weeks, which fits the cautious tone of current guidelines.
The most common side effects of both products are local and short-lived: pain, swelling, stiffness or fluid in the injected knee. In Durolane’s original development trials, arthralgia was reported in 10.8% and injection-site pain in 3.0% of 502 treated patients. The Synvisc label lists pain, swelling and joint effusion as the most commonly reported events, and notes that knee reactions became more frequent with repeated courses (6.3% of injections in a second course versus 2.2% in a single course).
Avian allergy is the clearest labeled difference. Durolane is not made from animal tissue, and its only hypersensitivity contraindication is a known allergy to hyaluronic acid preparations. For hylan G-F 20 the US labeling adds a specific precaution:
“Use caution when injecting Synvisc-One into patients who are allergic to avian proteins, feathers or egg products.” FDA, Synvisc-One Labeling (PMA P940015/S012)
In the US label this is a precaution, not a contraindication; some labels outside the US treat it more strictly. Hylan G-F 20 is also associated in the literature with severe acute inflammatory reactions, often called pseudoseptic or pseudosepsis reactions: a painful, swollen, warm knee within days of injection, with sterile, crystal-free synovial fluid. Goldberg and Coutts reviewed these reports in Clinical Orthopaedics and Related Research (2004). A later Sanofi-funded claims analysis of 694,404 injections, published in Cartilage (2021), found such reactions rare across all HA brands and did not link them to avian sourcing or cross-linking. Clinicians should still rule out infection before attributing a flare to the product. More detail on Durolane-specific reactions is in our article on potential side effects of Durolane.
Both labels ask patients to avoid strenuous activity and prolonged weight-bearing for about 48 hours after injection. The labels do not restrict ordinary walking, but jogging, tennis, heavy lifting or standing for more than an hour should wait. See our notes on recovery after Durolane and Synvisc aftercare.
Professional guidelines are more reserved about viscosupplementation than product marketing. The American Academy of Orthopaedic Surgeons states:
“Hyaluronic acid intra-articular injection(s) is not recommended for routine use in the treatment of symptomatic osteoarthritis of the knee.” AAOS, Management of Osteoarthritis of the Knee (Non-Arthroplasty) Guideline, 2021
The AAOS rates this as a moderate-strength recommendation. Its rationale notes a number needed to treat of 17 and adds that viscosupplementation can still be a viable option for some patients who have failed other treatments, with results generally better in mild to moderate (Kellgren-Lawrence I to III) than in severe knees. The 2013 edition had been more negative.
The 2019 American College of Rheumatology/Arthritis Foundation guideline conditionally recommends against intra-articular hyaluronic acid in knee OA (and strongly against it in hip OA). The ACR authors explain that a conditional recommendation against still allows use through shared decision-making when other options have been exhausted or have not helped enough. Neither guideline singles out Durolane or Synvisc; both apply to the product class.
There is no single “Durolane injection cost” or “Synvisc cost”. What a clinic or patient pays depends on the acquisition price, the payer, the administration fee, imaging guidance if used, and the patient’s deductible or coinsurance. The pieces that are standardized are the billing codes:
Coverage rules matter as much as price. Medicare contractors such as Palmetto GBA (LCD L39260) require documented symptomatic knee OA, radiographic confirmation, at least 3 months of failed conservative therapy, and failure of or contraindication to intra-articular steroid injection. A repeat series is covered only if at least 6 months have passed and the previous series helped. Commercial plans often add step therapy or a preferred-brand list, which can make one product cheaper for a given patient regardless of list price.
Several other FDA-approved viscosupplements share the same knee OA indication. Their labels differ mainly in source, dose and number of injections:
For “Orthovisc vs Synvisc”, the practical difference is similar to Durolane vs Synvisc: Orthovisc uses a non-cross-linked HA at a higher concentration, while Synvisc uses cross-linked hylan. As with Durolane, there are no definitive head-to-head trials showing one brand is clinically superior. Questions about repeat dosing are covered in how many Durolane injections you can have.
On current evidence, neither Durolane nor Synvisc has proven superiority over the other. Durolane is a reasonable first pick when a single visit is preferred or when the patient reports allergy to eggs, feathers or poultry. Synvisc-One offers the same single-visit convenience with a longer US track record (approved in 2009), while three-injection Synvisc suits clinics and payers that are set up for weekly courses. The final choice usually depends on payer coverage, patient history (avian allergy, previous flares, effusion) and how the patient responded to earlier courses.
Whichever product is used, it should be offered as part of a broader OA plan that includes exercise, weight management and analgesics, with realistic expectations set by the guideline evidence above. Viscosupplements are prescription devices and should be administered only by trained healthcare professionals.
Last updated: November 2026.
No. Durolane is a single 3 mL injection of non-animal, stabilized hyaluronic acid (60 mg) made by bacterial fermentation. Synvisc is hylan G-F 20, a cross-linked hyaluronan produced from chicken combs, given as three weekly 2 mL injections, while Synvisc-One delivers the same 48 mg in one 6 mL injection. All carry the same FDA indication for knee osteoarthritis pain.
There is no fixed price; cost depends on acquisition price, payer, administration fee and the patient’s coinsurance. Durolane is billed under HCPCS J7318 per 1 mg, so one 60 mg syringe equals 60 units. CMS publishes Medicare Part B payment limits for J7318 every quarter, and commercial plans often apply step therapy or preferred-brand rules that change what a patient pays.
Both were followed for 26 weeks in their key trials, which is the basis for the common “up to six months” description. In a 442-patient trial, Durolane’s benefit was maintained to 26 weeks, and Synvisc-One showed pain relief over 26 weeks versus placebo. Individual response varies, and no large head-to-head trial shows that one lasts longer.
No. Durolane contains stabilized sodium hyaluronate, a substance naturally present in joint fluid, and it is regulated by the FDA as a device rather than a drug. In one randomized trial it was compared with the steroid methylprednisolone acetate: responder rates were similar at 12 weeks, and the Durolane effect was maintained to 26 weeks while the steroid’s declined.
Medicare can cover both when local coverage criteria are met. Palmetto GBA’s LCD L39260, for example, requires symptomatic knee osteoarthritis confirmed on X-ray, at least 3 months of failed conservative therapy, and failure of or contraindication to steroid injections. A repeat series needs at least 6 months since the last one and documented benefit. Rules vary by Medicare contractor and plan.
Yes, ordinary walking is not restricted. Both product labels advise avoiding strenuous activity, such as jogging or tennis, and prolonged weight-bearing for about 48 hours after the injection; the Durolane label gives standing for more than an hour as an example. Mild pain, swelling or stiffness in the knee can occur and usually settles within a few days.